AbolerIS Pharma
Tomas Van Dyck is an experienced finance executive currently serving as Chief Financial Officer at DeuterOncology NV and AbolerIS Pharma, and Co-Chief Executive Officer at 2 Bridge. With a career spanning over a decade, notable past roles include Finance Director at Vanas Engineering nv, Chief Finance Officer at Arseus Medical, and Financieel & Administratief Directeur at Indaver België. Academic credentials include an Executive Masterclass in Corporate Finance from Vlerick Business School, an International Executive Program from INSEAD, and a Master's degree in Business/Managerial Economics from KU Leuven.
This person is not in any offices
AbolerIS Pharma
AbolerIS Pharma will develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune and degenerative diseases. Anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells. IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells. Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance.